The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet function, oxidant and antioxidant biomarkers and pro-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gohari, Sepehr, Reshadmanesh, Tara, Khodabandehloo, Hadi, Karbalaee-Hasani, Amir, Ahangar, Hassan, Arsang-Jang, Shahram, Ismail-Beigi, Faramarz, Dadashi, Mohsen, Ghanbari, Samin, Taheri, Homa, Fathi, Mojtaba, Muhammadi, Muhammad Javad, Mahmoodian, Reyhaneh, Asgari, Atieh, Tayaranian, Mohammadreza, Moharrami, Mehdi, Mahjani, Mahsa, Ghobadian, Bijan, Chiti, Hossein, Gohari, Sheida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669535/
https://www.ncbi.nlm.nih.gov/pubmed/36397128
http://dx.doi.org/10.1186/s13098-022-00951-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669535/
https://www.ncbi.nlm.nih.gov/pubmed/36397128
http://dx.doi.org/10.1186/s13098-022-00951-5

Ejemplares similares